Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics

Recently, on the pharmacological market, new drugs from the class of incretin mimetics, or glucagon-like peptide-1 (GLP-1) receptor agonists, which have proven their high effectiveness in type 2 diabetes mellitus therapy, have appeared. At present, much attention has been paid to the pleotropic effects of incretin mimetics. In a number of both experimental and clinical studies, cardioprotective effects of this medication group have been demonstrated. The present review elucidates existing data about neuroprotective effects of GLP-1 receptor agonists in brain ischaemia and in nonischaemic nervous system diseases such as diabetic neuropathy and neurodegenerative disorders. The possible mechanisms for these effects, which appear to be primarily antioxidant effects, anti-inflammatory effects, antiapoptotic effects and an increase in neurons differentiation, are discussed.

Download Full-text

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

Best Practice & Research Clinical Endocrinology & Metabolism ◽

10.1016/j.beem.2009.03.008 ◽

2009 ◽

Vol 23 (4) ◽

pp. 463-477 ◽

Cited By ~ 96

Author(s):

Sten Madsbad

Keyword(s):

Clinical Results ◽

Incretin Mimetics ◽

Receptor Agonists

Download Full-text

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2019.1552677 ◽

2018 ◽

Vol 28 (1) ◽

pp. 93-97 ◽

Cited By ~ 2

Author(s):

Antoni Camins ◽

Miren Ettcheto ◽

Oriol Busquets ◽

Patricia R. Manzine ◽

Rubén Dario Castro-Torres ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Treatment Strategy ◽

Glucagon Receptor ◽

Receptor Agonists ◽

Novel Treatment

Download Full-text

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights Endocrinology and Diabetes ◽

10.1177/11795514211051697 ◽

2021 ◽

Vol 14 ◽

pp. 117955142110516

Author(s):

Daria Ja’arah ◽

Mazhar Salim Al Zoubi ◽

Gamal Abdelhady ◽

Firas Rabi ◽

Murtaza M Tambuwala

Keyword(s):

Glucagon Secretion ◽

Dependent Manner ◽

Incretin Mimetics ◽

Receptor Agonists ◽

Potential Safety ◽

Recent Addition ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin secretion from the pancreatic β-cells in a glucose-dependent manner, more potently in hyperglycemic conditions, while suppressing glucagon secretion at the same time. Therefore, it was assumed that this class of drugs would have a lower risk of hypoglycemia than insulin secretagogues like sulphonylureas. However, GLP-1 receptor agonists have been proposed to cause hypoglycemia in healthy normoglycemic subjects implying that their action is not as glucose-dependent as once thought. Other studies concluded that they might not induce hypoglycemia and the risk is dependent on other individual factors. However, the FDA announced that the 12 GLP-1 receptor agonists currently available on the market had potential safety signs and evaluated the need for regulatory action. This review provides an overview of the studies that investigated the possible hypoglycemic effect of GLP-1 receptor agonists. In addition, the current review describes other adverse effects of GLP-1 receptor agonist treatment.

Download Full-text